Logo

OBIO

Orchestra BioMed Holdings, Inc.

OBIO

Orchestra BioMed Holdings, Inc. • NASDAQ
$5.32 ▲ 1.53% (+0.08)
Market Cap $300.39 M
52w High $6.30
52w Low $2.20
Dividend Yield 0%
P/E -2.96
Volume 122.54K
Outstanding Shares 56.46M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $861K ▲ $21.125M ▲ $-20.828M ▼ -2.419K% ▼ $-0.4 ▲ $-20.232M ▼
Q2-2025 $836K ▼ $20.117M ▲ $-19.363M ▼ -2.316K% ▼ $-0.5 ▼ $-19.246M ▼
Q1-2025 $868K ▲ $19.745M ▲ $-18.755M ▼ -2.161K% ▲ $-0.49 ▼ $-18.672M ▼
Q4-2024 $253K ▼ $16.872M ▼ $-16.155M ▼ -6.385K% ▼ $-0.42 ▼ $-16.593M ▼
Q3-2024 $987K $17.261M $-15.426M -1.563K% $-0.41 $-16.266M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $95.82M ▲ $104.807M ▲ $61.068M ▲ $43.739M ▲
Q2-2025 $33.924M ▼ $42.825M ▼ $42.53M ▲ $295K ▼
Q1-2025 $49.884M ▼ $59.051M ▼ $42.194M ▼ $16.857M ▼
Q4-2024 $66.812M ▼ $76.173M ▲ $43.215M ▲ $32.958M ▼
Q3-2024 $66.926M $75.319M $29.1M $46.219M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-20.828M ▼ $-14.55M ▲ $-38.584M ▼ $76.397M ▲ $23.263M ▲ $-14.86M ▲
Q2-2025 $-19.363M ▼ $-15.527M ▲ $16.356M ▲ $-428K ▼ $401K ▲ $-15.561M ▲
Q1-2025 $-18.755M ▼ $-16.616M ▼ $12.999M ▲ $-296K ▼ $-3.913M ▼ $-16.728M ▼
Q4-2024 $-16.155M ▼ $-13.538M ▲ $-3.753M ▼ $13.947M ▼ $-3.344M ▼ $-13.644M ▲
Q3-2024 $-15.426M $-13.7M $557K $15.035M $1.892M $-13.768M

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Orchestra BioMed is still very much a development-stage company. It has essentially no product revenue yet, so its income statement is driven entirely by research, development, and overhead costs. Losses have been steady over the past several years, growing gradually as the company invests more in its programs and infrastructure. This is typical for an early-stage biotech/medtech firm, but it also means the path to profitability depends heavily on successful clinical trial outcomes, regulatory approvals, and eventual commercialization or milestone payments from partners.

Balance Sheet

Balance Sheet The balance sheet shows a small but improving asset base and a company that has moved from a negative equity position to a positive one in recent years. That shift suggests past financing events or restructuring have strengthened the capital structure compared with the earliest years. Cash represents an important share of total assets, but the overall cash cushion is not large, which limits room for missteps and increases reliance on outside financing or partner support. Debt is present but not overwhelming; still, with no revenue, any borrowing must be viewed in the context of future funding needs and potential dilution or refinancing down the road.

Cash Flow

Cash Flow Cash flow is clearly negative from operations, reflecting ongoing clinical development and operating costs without offsetting revenue. The burn rate has been relatively consistent, which is helpful for planning but still means the company consumes cash each year. There is essentially no spending on physical assets, so almost all cash use is tied directly to running the business and advancing the pipeline. The company’s ability to continue at this pace depends on new capital raises, milestone receipts, or other funding from its large strategic partners.

Competitive Edge

Competitive Edge Competitively, Orchestra BioMed leans heavily on three things: its intellectual property, its focus on large cardiovascular markets, and its partnerships with major device companies. Its patent portfolio around hypertension and heart failure neuromodulation is broad and designed to keep others from easily copying its core technologies. The collaborations with Medtronic and Terumo are especially important: they give access to engineering, clinical trial infrastructure, regulatory expertise, and global sales channels that a small company could not build on its own. If its products succeed in trials, these relationships could help it scale far faster than typical small biotech or device developers. The flip side is dependence: its commercial future is tightly linked to these partners’ priorities, trial outcomes, and regulatory decisions, which adds another layer of execution risk.

Innovation and R&D

Innovation and R&D Innovation is the heart of the story here. The company is concentrated on two main cardiovascular programs: a pacemaker-based therapy to treat hypertension and a drug-delivery balloon for artery disease. The hypertension therapy tries to turn standard pacemakers into dual-purpose devices that also lower blood pressure through a software-driven pacing algorithm. This is a clever way to ride on an existing installed base rather than requiring a brand‑new piece of hardware. The drug-delivery balloon aims to improve on traditional drug-coated balloons by delivering a liquid drug into the artery wall without leaving any material behind, which could address safety and consistency concerns with older approaches. Beyond these, Orchestra BioMed has laid groundwork for expanding into heart failure and possibly other conditions, using a mix of in-house development, licensing, and acquisitions, all within its partnership-first model. The main uncertainty is clinical: the long-term value of this innovation will be determined by pivotal trial results and regulator feedback.

Summary

Overall, Orchestra BioMed looks like a classic high-risk, high-uncertainty, innovation-driven healthcare story. Financially, it is pre-revenue, loss-making, and reliant on external funding, with modest but improved balance sheet strength compared with its earliest years. Operational cash burn is steady but significant relative to its size. Strategically, it stands out more positively. The company is targeting very large cardiovascular markets with differentiated technologies and has secured deep partnerships with leading global device companies to help carry the products through trials and, if successful, into commercialization. The key things to watch are clinical trial outcomes for its lead programs, any regulatory designations or decisions, additional partnership activity, and its ability to manage cash and funding needs while it remains pre-commercial.

NEWS

November 26, 2025 · 4:05 PM UTC

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 11, 2025 · 9:00 AM UTC

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Read more

November 10, 2025 · 4:10 PM UTC

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Read more

November 3, 2025 · 8:00 AM UTC

Orchestra BioMed to Host Business Update Call on November 12, 2025

Read more

October 28, 2025 · 8:00 AM UTC

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

Read more